The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate

Małgorzata Piotrowska; Jarosław Szefel; Ewa Skrzypczak-Jankun; Wiesława Łysiak-Szydłowska; Mariusz Szajewski; Ewa Aleksandrowicz-Wrona; Jerzy Jankun

doi:10.5114/wo.2013.37221

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2013
vol. 17

Send email

Copy url:

abstract:

Original paper

The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate

Małgorzata Piotrowska

,

Jarosław Szefel

,

Ewa Skrzypczak-Jankun

,

Wiesława Łysiak-Szydłowska

,

Mariusz Szajewski

,

Ewa Aleksandrowicz-Wrona

,

Jerzy Jankun

Contemp Oncol (Pozn) 2013; 17 (4): 389–393

DOI: https://doi.org/10.5114/wo.2013.37221

Online publish date: 2013/10/07

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Piotrowska M, Szefel J, Skrzypczak-Jankun E, et al. The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate. Contemporary Oncology/Współczesna Onkologia. 2013;17(4):389-393. doi:10.5114/wo.2013.37221.

APA

Piotrowska, M., Szefel, J., Skrzypczak-Jankun, E., Łysiak-Szydłowska, W., Szajewski, M.,  & Aleksandrowicz-Wrona, E. et al. (2013). The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate. Contemporary Oncology/Współczesna Onkologia, 17(4), 389-393. https://doi.org/10.5114/wo.2013.37221

Chicago

Piotrowska, Małgorzata, Jarosław Szefel, Ewa Skrzypczak-Jankun, Wiesława Łysiak-Szydłowska, Mariusz Szajewski, Ewa Aleksandrowicz-Wrona,  and Jerzy Jankun. 2013. "The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate". Contemporary Oncology/Współczesna Onkologia 17 (4): 389-393. doi:10.5114/wo.2013.37221.

Harvard

Piotrowska, M., Szefel, J., Skrzypczak-Jankun, E., Łysiak-Szydłowska, W., Szajewski, M., Aleksandrowicz-Wrona, E.,  and Jankun, J. (2013). The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate. Contemporary Oncology/Współczesna Onkologia, 17(4), pp.389-393. https://doi.org/10.5114/wo.2013.37221

MLA

Piotrowska, Małgorzata et al. "The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate." Contemporary Oncology/Współczesna Onkologia, vol. 17, no. 4, 2013, pp. 389-393. doi:10.5114/wo.2013.37221.

Vancouver

Piotrowska M, Szefel J, Skrzypczak-Jankun E, Łysiak-Szydłowska W, Szajewski M, Aleksandrowicz-Wrona E et al. The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate. Contemporary Oncology/Współczesna Onkologia. 2013;17(4):389-393. doi:10.5114/wo.2013.37221.

PlumX metrics:

Aim of the study: The aim of this study was to determine whether measuring concentrations of 12-LOX in platelet-rich plasma patients can:

1. Differentiate between the group of patients with prostate cancer and healthy men.

2. Correlate the degree of severity of the disease and the concentration of the enzyme.

Material and methods: The study group comprised 88 men (40–88 years), including 54 patients diagnosed with prostate cancer. The population was divided into 4 groups:

• group 1 (22 men, aged 55–84 years) –with a negative biopsy,

• group 2 (36 men, aged 54–88 years) – with a positive biopsy result,

• group 3 (18 participants aged 58–83) – patients with cancer metastatic disease,

• group 4 of healthy men (12 people aged 40–66 years) – biopsy was not performed.

Routine PSA, morphology and CRP analysis were performed and platelet rich plasma was used for 12(S)LOX determination using an ELISA kit.

Results: 1. There was a weak (r = 0.0487) positive correlation between the number of blood platelets and plasma 12(S)LOX.

2. An inverse relationship between 12(S)LOX and Gleason grade was found.

3. Heterogeneity of 12(S)LOX in the group with prostate cancer metastatic disease may suggest differences in the response to the treatment carried out.

4. There were no statistically significant differences in concentrations of 12(S)LOX in different groups of patients.

Conclusions: Our results suggest that 12(S)LOX is relevant in prostate cancer; however, further study should include a larger, more select group of men with prostate cancer.

keywords:

The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate

Małgorzata Piotrowska , Jarosław Szefel , Ewa Skrzypczak-Jankun , Wiesława Łysiak-Szydłowska , Mariusz Szajewski , Ewa Aleksandrowicz-Wrona , Jerzy Jankun

12-lipoxygenase, prostate cancer, platelet-rich plasma

Małgorzata Piotrowska

,

Jarosław Szefel

,

Ewa Skrzypczak-Jankun

,

Wiesława Łysiak-Szydłowska

,

Mariusz Szajewski

,

Ewa Aleksandrowicz-Wrona

,

Jerzy Jankun